DC-806 is under clinical development by DICE Therapeutics and currently in Phase II for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Phase II drugs for Plaque Psoriasis (Psoriasis Vulgaris) have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how DC-806’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

DC-806 overview

S-011806 is under development for the treatment of plaque psoriasis and other IL-17 mediated chronic immunology disorders. It is administered by the oral route. It acts by targeting IL-17.

DICE Therapeutics overview

DICE Therapeutics, formerly DiCE Molecules Holdings LLC, is a pre-clinical stage biopharmaceutical company that develops drugs for the treatment of immunological and chronic diseases. The company is investigating its lead product candidate IL-17 (interleukin 17), an immune-cell-derived cytokine to treat psoriasis and other IL-17 mediated chronic immune disorders and other indications. It is also evaluating drug candidates for the treatment of inflammatory bowel disease, fibrosis and other immune-oncology disorders. The company harnesses its proprietary DELSCAPE platform technology to identify selective oral small molecule antagonists to modulate protein-protein interactions (PPI) targets. DICE Therapeutics is headquartered in South San Francisco, California, the US.

For a complete picture of DC-806’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.